Three month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OSAS);Trzymiesięczne leczenie za pomocą ciągłego dodatniego ciśnienia w drogach oddechowych (CPAP) obniża stężenie cholesterolu całkowitego oraz cholesterolu frakcji LDL we krwi, ale nie wpływa na stężenie homocysteiny i leptyny w surowicy u chorych z obturacyjnym bezdechem podczas snu (OBPS)

Pneumonologia i Alergologia Polska

Volumn 79, Issue 3, 2011, Pages 173-183

  Kumor, Marta ^a   Bielicki, Piotr ^a   Przybyłowski, Tadeusz ^a   Rubinsztajn, Renata ^a   Zieliński, Jan ^a   Chazan, Ryszarda ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

CPAP; Homocysteine; Leptin; Lipids; Obstructive sleep apnea

Indexed keywords

BIOLOGICAL MARKER; HOMOCYSTEINE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; POSITIVE END EXPIRATORY PRESSURE; RISK FACTOR; SLEEP APNEA SYNDROME; TIME; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HOMOCYSTEINE; HUMANS; LEPTIN; MALE; MIDDLE AGED; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955586921     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middleaged adults. N. Engl. J. Med. 1993; 328: 1230-1235.
2. Leung R.S.T., Bradley D.T. Sleep apnea and cardiovascular disease state of the art. Am. J. Respir. Crit. Care Med. 2001; 164: 2147-2216.
3. Ryan S., Nolan G., Hannigan E., Cunningham S., Taylor C., McNicholas W.T. Cardiovascular risk markers in obstructive sleep apnea syndrome and correlation with obesity. Thorax 2007; 62: 509-514.
4. Pływaczewski R., Bednarek M., Jonczak L., Zieliński J. Sleep-disordered breathing in a middle-aged and older Polish urban population. J. Sleep Res. 2008; 17: 73-84.
5. Nieto J.F., Young B.Y., Lind B.K. i wsp. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community study. JAMA 2000; 283: 1829-1836.
6. Peppard P.E., Young T., Palta M., Skatrud J. Prospective study of association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 2000; 342: 1378-1384.
7. Peker Y., Carlson J., Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur. Respir. J. 2006; 28: 596-602.
8. Narkiewicz K., van de Borne P.J., Pesek C.A., Dyken M.E., Montano M., Somers V.K. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183-1189.
9. Saaresranta T., Polo O. Sleep-disordered breathing and hormones. Eur. Respir. J. 2003; 22: 161-172.
10. Lavie L. Obstructive sleep apnea syndrome - an oxidative stress disorder. Sleep Med. Rev. 2003; 7: 35-51.
11. Bokinsky G., Miller M., Ault K., Husband P., Mitchell J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. Chest 1995; 108: 625-630.
12. Shahar E., Whitney C.W., Redline S. i wsp. Sleep-disordered breathing and cardiovascular disease cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2001; 163: 19-25.
13. Chin K., Shimizu K., Nakamura T. i wsp. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure. Circulation 1999; 100: 706-711.
14. Ip M.S., Lam K. S., Ho C., Tsang K.W., Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-586.
15. Cheng Ch.H., Huang M.Ch., Liu Sh.Ch., Lin K.H., Huang Y.Ch. Traditional cardiovascular risk factors but not homocysteine are associated with obstructive sleep apnea. Nutr. Res. 2006; 26: 59-64.
16. Barcelü A., Barbé F., de la Pena M. i wsp. Antioxidant status in patients with sleep apnoea and impact of continuous positive airways pressure treatment. Eur. Respir. J. 2006; 27: 756-760.
17. Börgel J., Sanner B.M., Bittlinsky A. i wsp. Obstructive sleep apnea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur. Respir. J. 2006; 27: 121-127.
18. Tamura A., Kawano Y., Watanabe T., Kadota J. Relationship between the severity of obstructive sleep apnea and impaired glucose metabolism in patients with obstructive sleep apnea. Respir. Med. 2008, 102: 1412-1416.
19. Harsch I.A., Konturek P.C., Koebnick C. i wsp. Leptin and ghrelin levels in patients with obstructive sleep apnea: effect of CPAP treatment. Eur. Respir. J. 2003; 22: 251-257.
20. Robinson G.V., Pepperell J.C., Segal H.C., Davies R.J., Stradling J.R. Circulating cardiovascular risk factors in obstructive sleep apnea: data from randomized controlled trials. Thorax 2004; 59: 777-782.
21. Steiropoulos P., Tsara V., Nena E. i wsp. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132: 843-885.
22. Shimizu K., Chin K., Nakamura T. i wsp. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnea-hypopnea syndrome. Thorax 2002; 57: 29-434.
23. Narkiewicz K., Sommers V.K. Sympathetic nerve activity in obstructive sleep apnea. Acta Physiol. Scand. 2003; 177: 385--390.
24. Pepperell J.C., Ramdassingh-Dow S., Crosthwaite N. i wsp. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: a randomised parallel trial. Lancet 2002; 359: 204-210.
25. Schahin S.P., Nechanitzky T., Dittel C. i wsp. Long-term improvement of insulin sensitivity during CPAP therapy in the obstructive sleep apnea syndrome. Med. Sci. Monit. 2008; 14: 117-121.
26. Hassaballa H.A., Tulaimat A., Herdegen J.J., Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 2005; 9: 176-180.
27. Graham I.M., Daly E.L., Refsum H. i wsp. Plasma homocysteine as a risk factor for vascular disease The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
28. Stamler J.S., Osborne J.A., Jaraki O. i wsp. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest. 1993; 91: 308-318.
29. Svatikova A., Wolk R., Magera M.J., Shamsuzzaman A.S., Phillips B.G., Somers V.K. Plasma homocysteine in obstructive sleep apnea. Eur. Heart J. 2004; 25: 1325-1329.
30. Lavie L., Perelman A., Lavie P. Plasma homocysteine levels inobstructive sleep apnea. Chest 2001; 120: 900-908.
31. Kokturk O., Ciftci T.U., Mollarecep E. Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Respir. Med. 2006; 100: 536-541.
32. Can M., Acikgoz S., Mungan G. i wsp. Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006; 129: 233-237.
33. Phillips B.G., Narkiewicz K., Pesek C.A., Haynes W.G., Dyken M.E., Somers V.K. Effects of obstructive sleep apnea on endot-helin-1 and blood pressure. J. Hypertens. 1999; 17: 61-66.
34. Ohga E., Nagase T., Tomita T. i wsp. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J. Appl. Physiol. 1999; 87: 10-14.
35. Yokoe T., Minoguchi K., Matsuo H. i wsp. Elevated levels of Creactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
36. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-545.
37. Wahrenberg H., Hertel K., Leijonhufvud B.M., Persson L.G., Toft E., Arner P. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005; 330: 1363-1364.
38. WHO Physical status: the use and interpretation of anthropometry. Report of WHO Expert Committee. WHO Technical Report Series 854. World Health Organization, Geneve 1995.
39. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006; 23: 469-480.
40. Gibbons R.J., Abrams J., Chatterjee K. i wsp. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with chronic stable angina). Circulation 2003; 107: 149-158.
41. De Backer G., Ambrosioni E., Borch-Johnsen K. i wsp. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. Heart J. 2003; 24: 1601-1610.
42. Wasserman K. i wsp. Clinical exercise testing. W: Wasserman K. i wsp. (red.). Principles of exercise testing and interpretation (wyd. 3). Lippincott Wiliams & Wilkins, Philadelphia 1999; 115-142.
43. Jordan W., Berger C., Cohrs S. i wsp. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J. Neural. Transm. 2004; 111: 683-689.
44. Sanner B.M., Kollhosser P., Buechner N., Zidek W., Tepel M. Influence of treatment on leptin levels in patients with obstructive sleep apnea. Eur. Respir. J. 2004; 23: 601-604.
45. Barceló A., Barbé F., Llompart E. i wsp. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am. J. Respir. Crit. Care Med. 2005; 171: 183-187.
46. Roux F.J., Hilbert J. Continuous positive airway pressure: new generations. Clin. Chest Med. 2003; 24: 315-334.
47. Meurice J.C., Dore P., Paquereau J. i wsp. Predictive factors of long-term compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest 1994; 105: 429-433.
48. Weaver T.E., Kribbs N.B., Pack A.I. i wsp. Night-to-night variability in CPAP use over the first three months of treatment. Sleep 1997; 20: 278-283.